Laura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with <em>ALK</em>-positive non–small cell lung cancer in the ASCEND-7 trial.
Laura Quan Man Chow, MD, FRCPC
Advertisement
Articles by Laura Quan Man Chow, MD, FRCPC
Advertisement
Latest Updated Articles
Rationale for Evaluating Ceritinib in ALK-Positive Patients With NSCLCPublished: November 5th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
